Ideas catalog
Every idea we've derived from recent research — the ones marked “Prototype” come with a live demo you can try.
A high-risk, high-reward biotech play that targets a niche orphan disease with a sophisticated delivery mechanism, though it currently lacks a specific molecular payload.
A technically feasible but profoundly undifferentiated translation API that rebuilds now-commoditized Transformer technology into a market dominated by Google, DeepL, AWS, and Azure.
A niche developer tool addressing a real accessibility gap, but lacks a clear commercial buyer and a defined technical mechanism for 'linting' data pipelines for screen-reader compatibility.
A technically feasible compliance-gap tool with a real regulatory tailwind, but built on a single unvalidated academic framework and facing a crowded incumbent landscape that sharply limits its moat.
A timely take on enterprise agent governance, but it inherits an unproven single-paper theory and bundles too many heavyweight certification concepts into one over-scoped product.
A technically coherent but commercially narrow diagnostic instrument targeting a niche Italian bilectal-education market, where the underlying evidence is real but thin, validation work remains substantial, and the addressable market is small.
A highly theoretical mathematical application that lacks a clear commercial product definition and relies on a single abstract of pure mathematics.
Mechanistically grounded but commercially weak: the test's core problem is that dietary deficiency and biosynthetic bottleneck are treated identically (carnitine supplements), so the diagnostic doesn't meaningfully change clinical decisions and faces a steep value-justification hurdle against cheap OTC supplementation.
Backed by 2 papers
Technically feasible telehealth-MBCT product in a crowded market, but built almost entirely on a single case-study letter to the editor, making the evidence base too thin to justify the specific population claim.
A narrow materials-engineering improvement to self-ligating bracket caps that targets a degradation the source paper itself deems clinically inconsequential, leaving the core market need unproven.
A narrowly scoped software recommendation module built almost entirely on one preclinical study of a single tooth type and single resin, whose own key finding—that all tested thicknesses reach essentially the same final correction—substantially undermines the clinical value proposition.
Backed by 2 papers
A narrowly-focused engineering toolkit for dual-SCR dosing on Euro 7 diesel LCVs that addresses a real compliance need but faces a tough wedge against incumbents who already own this competency in-house.
A conceptually sound but academically thin proposal that lacks a concrete implementation mechanism for measuring 'emotional language' beyond existing psychological frameworks.
A low-moat tool based on a widely debated 1983 theory that lacks a clear, automated mechanism for objective assessment in preschoolers.
A scientifically credible but commercially modest diagnostic add-on constrained by a single unreplicated paper, a 0.75% population yield, and no standalone product potential — essentially a one-gene addition to existing panels.
A narrowly-scoped planning analytics tool that surfaces a genuinely actionable insight, but rests on a single modeling paper and faces a thin, grant-dependent buyer market.
A technically focused, well-scoped plugin with a real clinical hook, but the commercial opportunity is narrow and the empirical foundation rests on a single small RCT covering one anatomical site, limiting the robustness of any risk model it could actually ship.
A clinically grounded but commercially thin idea that turns a single RCT's design finding into a guide template—useful as a best-practice default, but hard to defend or monetize as a standalone product.
A low-moat service business that attempts to productize a standard editorial process already performed by the target customers.
A generic GIS-based decision tool that lacks a proprietary edge and relies on a broad policy summary rather than a specific technical breakthrough.